ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock
Summary
The Company has also granted the underwriters a 30-day option to purchase up to 3,146,853 additional shares of common stock at the public offering price before deducting underwriting discounts and commissions.ADMA intends to use the net proceeds from this offering to accelerate commercialization and production activities, complete plasma center buildout and obtain FDA approvals, to conclude post FDA marketing approval research and development projects, and for working capital, capital expenditures and for general corporate purposes.Raymond James & Associates, Inc., Cantor Fitzgerald & Co. and Mizuho Securities USA LLC are acting as joint book-running managers of the offering.The securities described above are being offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. For more information, please visit www.admabiologics.com.This press release contains forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (we, our or the Company). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as estimate, project, intend, forecast, target, anticipate, plan, planning, expect, believe, will, is likely, will likely, should, could, would, may, or, in each case, their negative, or words or expressions of similar meaning. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate.